Do analysts rate ENTX or NLTX?

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Given Entera Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Entera Bio is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, ENTX or NLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio N/A N/A -$11.44M -$0.27 N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is ENTX or NLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Neoleukin Therapeutics N/A -37.22% -30.91%

Which has stronger valuation and earnings, ENTX or ELDN?

Entera Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio N/A N/A -$11.44M -$0.27 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A

Is ENTX or ELDN more profitable?

Entera Bio's return on equity of -83.31% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Eledon Pharmaceuticals N/A -116.97% -41.91%

Is ENTX or CLLS more profitable?

Entera Bio has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Cellectis -89.51% -80.66% -20.51%

Which has higher valuation and earnings, ENTX or IMRX?

Entera Bio is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio N/A N/A -$11.44M -$0.27 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is ENTX or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Immuneering N/A -31.93% -29.92%

Entera Bio (ENTX) Competitors

$1.66 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.63 -0.03 (-1.81%)

As of 07/2/2026 07:54 PM Eastern

Compare

ENTX vs. NLTX, ELDN, AKBA, CLLS, and IMRX

Should you buy Entera Bio stock or one of its competitors? MarketBeat compares Entera Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entera Bio include Neoleukin Therapeutics (NLTX), Eledon Pharmaceuticals (ELDN), Akebia Therapeutics (AKBA), Cellectis (CLLS), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.

How does Entera Bio compare to Neoleukin Therapeutics?

Entera Bio (NASDAQ:ENTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Entera Bio has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

In the previous week, Entera Bio's average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.

Company	Overall Sentiment
Entera Bio	Neutral
Neoleukin Therapeutics	Neutral

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Given Entera Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Entera Bio is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neoleukin Therapeutics' return on equity of -37.22% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Entera Bio beats Neoleukin Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Entera Bio compare to Eledon Pharmaceuticals?

Entera Bio (NASDAQ:ENTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Entera Bio has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

In the previous week, Entera Bio's average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Entera Bio	Neutral
Eledon Pharmaceuticals	Neutral

Entera Bio's return on equity of -83.31% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Entera Bio currently has a consensus price target of $9.00, suggesting a potential upside of 442.17%. Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 144.73%. Given Entera Bio's higher possible upside, equities analysts plainly believe Entera Bio is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Entera Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Summary

Entera Bio beats Eledon Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Entera Bio compare to Akebia Therapeutics?

Entera Bio (NASDAQ:ENTX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Akebia Therapeutics had 9 more articles in the media than Entera Bio. MarketBeat recorded 9 mentions for Akebia Therapeutics and 0 mentions for Entera Bio. Akebia Therapeutics' average media sentiment score of 0.27 beat Entera Bio's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Entera Bio	Neutral
Akebia Therapeutics	Neutral

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Entera Bio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Entera Bio presently has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 276.34%. Given Entera Bio's higher probable upside, equities analysts plainly believe Entera Bio is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Entera Bio has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than Entera Bio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A
Akebia Therapeutics	$236.20M	1.41	-$5.34M	-$0.08	N/A

Summary

Akebia Therapeutics beats Entera Bio on 10 of the 15 factors compared between the two stocks.

How does Entera Bio compare to Cellectis?

Entera Bio (NASDAQ:ENTX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Entera Bio has higher earnings, but lower revenue than Cellectis. Entera Bio is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A
Cellectis	$68.07M	4.86	-$67.59M	-$0.67	N/A

Entera Bio currently has a consensus price target of $9.00, suggesting a potential upside of 442.17%. Cellectis has a consensus price target of $7.00, suggesting a potential upside of 112.12%. Given Entera Bio's higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Cellectis had 2 more articles in the media than Entera Bio. MarketBeat recorded 2 mentions for Cellectis and 0 mentions for Entera Bio. Cellectis' average media sentiment score of 0.50 beat Entera Bio's score of 0.00 indicating that Cellectis is being referred to more favorably in the news media.

Company	Overall Sentiment
Entera Bio	Neutral
Cellectis	Positive

Entera Bio has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.88, meaning that its stock price is 188% more volatile than the broader market.

Entera Bio has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Cellectis	-89.51%	-80.66%	-20.51%

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cellectis beats Entera Bio on 12 of the 16 factors compared between the two stocks.

How does Entera Bio compare to Immuneering?

Entera Bio (NASDAQ:ENTX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Entera Bio has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Immuneering's return on equity of -31.93% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Immuneering	N/A	-31.93%	-29.92%

Entera Bio is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Entera Bio presently has a consensus target price of $9.00, indicating a potential upside of 442.17%. Immuneering has a consensus target price of $16.50, indicating a potential upside of 217.92%. Given Entera Bio's higher probable upside, analysts clearly believe Entera Bio is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Immuneering had 1 more articles in the media than Entera Bio. MarketBeat recorded 1 mentions for Immuneering and 0 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.00 equaled Immuneering'saverage media sentiment score.

Company	Overall Sentiment
Entera Bio	Neutral
Immuneering	Neutral

Summary

Immuneering beats Entera Bio on 9 of the 13 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTX vs. The Competition

Export

Metric	Entera Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$81.82M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-6.15	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	5.72	8.66	10.96	6.46
Net Income	-$11.44M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.55%	3.39%	2.12%	1.69%
1 Month Performance	40.68%	10.81%	5.25%	3.81%
1 Year Performance	-14.87%	62.61%	33.29%	23.90%

Entera Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTX Entera Bio	2.2733 of 5 stars	$1.66 flat	$9.00 +442.2%	-14.9%	$81.82M	N/A	N/A	20	Gap Up
NLTX Neoleukin Therapeutics	N/A	$32.25 +2.3%	N/A	+75.9%	$303.09M	N/A	N/A	90	High Trading Volume
ELDN Eledon Pharmaceuticals	1.4091 of 5 stars	$3.89 +2.1%	$9.67 +148.5%	+31.4%	$300.27M	N/A	N/A	10
AKBA Akebia Therapeutics	2.357 of 5 stars	$1.11 +1.4%	$4.67 +322.3%	-65.6%	$296.43M	$236.20M	N/A	430	News Coverage Analyst Forecast Gap Up
CLLS Cellectis	2.4434 of 5 stars	$2.94 +4.3%	$7.00 +138.1%	+108.2%	$295.00M	$68.07M	N/A	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entera Bio (ENTX) Competitors

ENTX vs. NLTX, ELDN, AKBA, CLLS, and IMRX

How does Entera Bio compare to Neoleukin Therapeutics?

Summary

How does Entera Bio compare to Eledon Pharmaceuticals?

Summary

How does Entera Bio compare to Akebia Therapeutics?

Summary

How does Entera Bio compare to Cellectis?

Summary

How does Entera Bio compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entera Bio (ENTX) Competitors

ENTX vs. NLTX, ELDN, AKBA, CLLS, and IMRX

How does Entera Bio compare to Neoleukin Therapeutics?

Which has more volatility and risk, ENTX or NLTX?

Which has stronger earnings & valuation, ENTX or NLTX?

Does the media prefer ENTX or NLTX?

Do analysts rate ENTX or NLTX?

Do insiders & institutionals hold more shares of ENTX or NLTX?

Is ENTX or NLTX more profitable?

Summary

How does Entera Bio compare to Eledon Pharmaceuticals?

Which has more volatility and risk, ENTX or ELDN?

Does the media refer more to ENTX or ELDN?

Is ENTX or ELDN more profitable?

Do insiders and institutionals believe in ENTX or ELDN?

Do analysts prefer ENTX or ELDN?

Which has stronger valuation and earnings, ENTX or ELDN?

Summary

How does Entera Bio compare to Akebia Therapeutics?

Does the media refer more to ENTX or AKBA?

Do insiders & institutionals hold more shares of ENTX or AKBA?

Is ENTX or AKBA more profitable?

Do analysts recommend ENTX or AKBA?

Which has more risk and volatility, ENTX or AKBA?

Which has better valuation & earnings, ENTX or AKBA?

Summary

How does Entera Bio compare to Cellectis?

Which has higher earnings and valuation, ENTX or CLLS?

Do analysts recommend ENTX or CLLS?

Does the media refer more to ENTX or CLLS?

Which has more risk & volatility, ENTX or CLLS?

Is ENTX or CLLS more profitable?

Do insiders and institutionals hold more shares of ENTX or CLLS?

Summary

How does Entera Bio compare to Immuneering?

Do institutionals and insiders have more ownership in ENTX or IMRX?

Which has more risk & volatility, ENTX or IMRX?

Is ENTX or IMRX more profitable?

Which has higher valuation and earnings, ENTX or IMRX?

Do analysts rate ENTX or IMRX?

Does the media refer more to ENTX or IMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools